ALK and neoplasm: However, in some patients with ALK-positive NSCLC treated sequentially with several ALK TKI, the tumor or its metastases become resistant to second generation ALK inhibitors, due to the occurrence of compound mutations in the kinase domain of ALK [62], or to the activation of bypass signaling pathways (see below).